Applied Biocode

Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.

The companies will use their respective technologies to develop multiplex molecular diagnostic panels for laboratory testing.

The deal covers use within the life sciences, food and beverage research, and environmental testing markets.

The deal provides PerkinElmer access to Applied BioCode's Barcoded Magnetic Bead technology, including the BioCode MDx 3000 instrument.

Genetic Analysis CEO Kari Stenersen said the deal is a "commercial breakthrough" for the Oslo-based company.

NEW YORK (GenomeWeb) — Applied BioCode is developing a new test for gastrointestinal pathogens that it hopes to sell to high-volume hospital laboratories and that will compete directly with Luminex's US Food and Drug Administration-cleared Gastrointestinal Pathogen Panel.

Genetic Analysis said this week that its GA-map IBS Dysbiosis test is now CE marked and available for use on clinical samples in European labs.

NEW YORK (GenomeWeb News) – Applied BioCode today said it has signed a license and supply agreement covering its barcoded magnetic bead (BMB) technology with molecular diagnostics firm Genetic Analysis.

Illumina this week named Charles Dadswell as senior vice president and general counsel.

Illumina has appointed Charles Dadswell as its new senior vice president and general counsel. Dadswell replaces Christian Cabou, who has retired, and is responsible for all of the company's legal and IP matters.

Pages

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.